Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
The Way to Fruitful Weight reduction: Individual Wellbeing Excursions - 2Taste the World: Five Food sources That Have Dazzled Worldwide Palates
- 3Exploring ways to reduce the impact of space junk on Earth
- 4A Couple of Reasonable Guitars for 2024
- 5Defense Minister Katz moves to extend IDF service to 36 months
- A Sweet Choice: Pick Your #1 Cake!
- 4K televisions for Extreme Film Watching Experience
- New York to require social media platforms to display mental health warnings
- Top notch Feasting: A Manual for Worldwide Acclaimed Eateries
- From Amateur to Master: My Involvement in Photography
- I’m a doctor. Here are 10 science-backed tips to help you get healthier.
- What to know about voluntary chocolate recall
- RFK Jr. guts the US childhood vaccine schedule despite its decades-long safety record
- Instructions to Warmly greet Certainty and Appeal
